Midostaurin
Sign in to save this workspacePrimary targets: FLT3 · FDA status: FDA Approved
Selectivity scorecard
KISS
78.64
Gini
0.500
CATDS
0.006
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Midostaurin. Strongest target: JAK3 at 100.0% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | JAK3 | 100.0% | 0.0% |
| 2 | MST2_STK3 | 100.0% | 0.0% |
| 3 | PHKG1 | 100.0% | 0.0% |
| 4 | GLK_MAP4K3 | 99.4% | 0.6% |
| 5 | MLK3_MAP3K11 | 99.2% | 0.8% |
| 6 | CAMK2D | 98.9% | 1.1% |
| 7 | JAK2 | 98.9% | 1.1% |
| 8 | SIK2 | 98.8% | 1.2% |
| 9 | FLT3 | 98.6% | 1.4% |
| 10 | RSK3 | 98.5% | 1.5% |
| 11 | PKN1_PRK1 | 98.5% | 1.5% |
| 12 | AURORA_A | 98.4% | 1.6% |
| 13 | ARK5_NUAK1 | 98.3% | 1.7% |
| 14 | MLK1_MAP3K9 | 98.0% | 2.0% |
| 15 | YSK4_MAP3K19 | 97.9% | 2.1% |
| 16 | MARK4 | 97.9% | 2.1% |
| 17 | MST1_STK4 | 97.4% | 2.6% |
| 18 | MARK3 | 97.4% | 2.6% |
| 19 | AMPK(A1_B2_G2) | 97.3% | 2.7% |
| 20 | FMS | 97.3% | 2.7% |
Selectivity landscape
Where Midostaurin sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Midostaurin.
Atlas insights for Midostaurin
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target1%
Off-target99%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 4956.64 | |
| ALLOGRAFT_REJECTION | 12711.34 | |
| ANDROGEN_RESPONSE | 3950.86 | |
| ANGIOGENESIS | 2060.73 | |
| APICAL_JUNCTION | 13449.69 | |
| APICAL_SURFACE | 1320.44 | |
| APOPTOSIS | 13455.05 | |
| BILE_ACID_METABOLISM | 1544.93 | |
| CHOLESTEROL_HOMEOSTASIS | 1717.98 | |
| COAGULATION | 1810.76 | |
| COMPLEMENT | 7777.57 | |
| DNA_REPAIR | 3180.90 | |
| E2F_TARGETS | 10417.85 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 4119.32 | |
| ESTROGEN_RESPONSE_EARLY | 6522.98 | |
| ESTROGEN_RESPONSE_LATE | 6203.59 | |
| FATTY_ACID_METABOLISM | 1149.03 | |
| G2M_CHECKPOINT | 10869.57 | |
| GLYCOLYSIS | 5387.21 | |
| HEDGEHOG_SIGNALING | 1557.87 | |
| HEME_METABOLISM | 4625.99 | |
| HYPOXIA | 7574.52 | |
| IL2_STAT5_SIGNALING | 5104.46 | |
| IL6_JAK_STAT3_SIGNALING | 8953.80 | |
| INFLAMMATORY_RESPONSE | 8985.22 | |
| INTERFERON_ALPHA_RESPONSE | 1649.98 | |
| INTERFERON_GAMMA_RESPONSE | 10661.41 | |
| KRAS_SIGNALING_DN | 2097.62 | |
| KRAS_SIGNALING_UP | 5794.25 | |
| MITOTIC_SPINDLE | 10731.95 | |
| MTORC1_SIGNALING | 7232.25 | |
| MYC_TARGETS_V1 | 6538.93 | |
| MYC_TARGETS_V2 | 1748.93 | |
| MYOGENESIS | 6547.95 | |
| NOTCH_SIGNALING | 757.26 | |
| OXIDATIVE_PHOSPHORYLATION | 2025.52 | |
| P53_PATHWAY | 6630.83 | |
| PANCREAS_BETA_CELLS | 996.68 | |
| PEROXISOME | 2226.34 | |
| PI3K_AKT_MTOR_SIGNALING | 15616.61 | |
| PROTEIN_SECRETION | 3328.74 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 885.16 | |
| SPERMATOGENESIS | 3669.04 | |
| TGF_BETA_SIGNALING | 3966.82 | |
| TNFA_SIGNALING_VIA_NFKB | 9742.73 | |
| UNFOLDED_PROTEIN_RESPONSE | 2996.55 | |
| UV_RESPONSE_DN | 8373.25 | |
| UV_RESPONSE_UP | 6608.25 | |
| WNT_BETA_CATENIN_SIGNALING | 3767.32 | |
| XENOBIOTIC_METABOLISM | 3096.17 |
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.867 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.853 |
| SRR23303752 | — | 0.846 |
| SRR12202498 | — | 0.840 |
| TCGA-FD-A43X-01A-11R-A23W-07 | — | 0.835 |
Annotations
Sign in to read and post annotations.
Loading…